Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the submission of an Investigational New Drug (IND) application for an Evelo-sponsored Phase 2 clinical study evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19. The study will be led by Reynold A. Panettieri, Jr., M.D., Vice Chancellor for Translational Medicine and Science at Rutgers Biomedical and Health Sciences and Professor of Medicine at Rutgers Robert Wood Johnson Medical School. To read the full story.
Home / News / Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
Recent Posts
- Study Finds Widespread Exposure to Hormone-Disrupting Chemical During Pregnancy.
- Community-Based Programs in Senior Centers May Lower Health Care Use and Costs for People with Dementia
- New NJACTS Publication
- How Rutgers Health and Vaccine Equity Education Coalition Ambassadors at the Boys & Girls Club of Newark Are Promoting Vaccine Equity.
- Center for Environmental Exposures and Disease 7th Annual Environmental Health and Justice Summit 10/18, 9am-4pm
Categories
- Community (2,020)
- Covid (975)
- CTO Events (3)
- News (2,570)
- Pilots (20)